Suppression of Moloney sarcoma virus immunity following sensitization with attenuated virus
- PMID: 1000500
Suppression of Moloney sarcoma virus immunity following sensitization with attenuated virus
Abstract
Murine sarcoma virus (Moloney strain) (MSV-M)-induced tumors are unusual in that they regularly appear less than 2 weeks after virus inoculation, progress for 1 to 2 weeks, and are rejected by normal adult BALB/c mice. Rejectio leaves the animals immune to tumor induction. In the present study, presensitization of normal adult BALB/c mice with attenuated MSV-M resulted in an altered pattern of tumor immunity. Injection of active MSV-M into the presensitized animals resulted in tumor induction and rejection similar to that observed in normal animals, but rejection failed to produce protection against the secondary inoculation with MSV-M. After the second inoculation with active MSV-M, tumors appeared and progressed but ultimately were rejected. Over 80% of the mice died, 25% after the primary challenge and the remainder after the secondary challenge. At death, all mice had histological evidence of leukemia which was the probable cause of death. The animals that died following the secondary challenge also had evidence of disseminated MSV-M. Solid tumor nodules were found in skeletal muscle distant from the original site of inoculation, and active MSV-M was isolated from spleen and lungs. The possibility that the results were produced by specific suppression of MSV-Moloney leukemia virus immunity is discussed.
Similar articles
-
Functional activity in vivo of effector T cell populations. III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clone.Eur J Immunol. 1987 Feb;17(2):173-8. doi: 10.1002/eji.1830170204. Eur J Immunol. 1987. PMID: 3030766
-
Murine sarcoma virus pseudotypes used as immunogens against viral and chemical oncogenesis.Cancer Res. 1977 Jun;37(6):1768-76. Cancer Res. 1977. PMID: 192461
-
In vitro studies of cell-mediated immunity to Moloney murine leukemia virus and Moloney leukemia-associated surface antigens.Cancer Res. 1979 Dec;39(12):4887-93. Cancer Res. 1979. PMID: 387218
-
Cell-mediated immunity to Moloney sarcoma virus in mice. II. Analysis of antigenic specificities involved in T lymphocyte-mediated in vivo rejection of murine sarcoma virus-induced tumors.Eur J Immunol. 1975 Feb;5(2):148-55. doi: 10.1002/eji.1830050214. Eur J Immunol. 1975. PMID: 1086221
-
T lymphocyte tolerance and early appearance of virus-induced cell surface antigens in Moloney-murine leukemia virus neonatally injected mice.J Immunol. 1981 Jan;126(1):187-93. J Immunol. 1981. PMID: 6969741
Cited by
-
Identification, using synthetic peptides, of the minimum amino acid sequence from the retroviral transmembrane protein p15E required for inhibition of lymphoproliferation and its similarity to gp21 of human T-lymphotropic virus types I and II.J Virol. 1989 Aug;63(8):3250-6. doi: 10.1128/JVI.63.8.3250-3256.1989. J Virol. 1989. PMID: 2746730 Free PMC article.
-
In vitro production of immunosuppressive factors by murine sarcoma virus-transformed mouse fibroblasts.Proc Natl Acad Sci U S A. 1980 Apr;77(4):2205-8. doi: 10.1073/pnas.77.4.2205. Proc Natl Acad Sci U S A. 1980. PMID: 6246526 Free PMC article.
-
Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency virus type 1.J Virol. 1989 Aug;63(8):3257-60. doi: 10.1128/JVI.63.8.3257-3260.1989. J Virol. 1989. PMID: 2526228 Free PMC article.
-
Suppression of human lymphocyte mitogen response by retroviruses of type D. I. Action of highly purified intact and disrupted virus.Arch Virol. 1985;86(3-4):177-86. doi: 10.1007/BF01309823. Arch Virol. 1985. PMID: 4062557